Table 5.
Estimates of potential additional national economic burden
| Condition | Low estimates
|
High estimates
|
||||||
|---|---|---|---|---|---|---|---|---|
| Current costs | Number of current cases | Costs prevented | Number of cases prevented | Current costs | Number of current cases | Costs prevented | Number of cases prevented | |
| CAUTI | $19M | 93.3K | $2M | 1.9K | $367M | 449.3K | $110M | 94.4K |
| CLABSI | $120M | 71.9K | $12M | 1.4K | $2,435M | 92.0K | $730M | 19.3K |
| GI | $210M | 123.1K | $21M | 2.5K | $1,464M | 178.0K | $439M | 37.4K |
| SSI | $459M | 157.5K | $46M | 3.2K | $8,273M | 290.5K | $2,482M | 61.0K |
| VAP/HAP | $613M | 157.5K | $61M | 3.2K | $1,626M | 52.5K | $488M | 11.0K |
| Total | $1,422M | 603.3K | $142M | 12.1K | $14,165M | 1,062.4K | $4,250M | 223.1K |
Notes: “Number of cases prevented” and “Costs prevented” refer to the cases and associated costs that are estimated to be currently prevented by the use of antiseptics, respectively. Totals may differ from the expected value due to rounding. As the number of cases in the low and high scenarios differs for each condition, the relationships between low and high estimates are influenced by factors other than the portion attributable and proportion associated with antiseptics and results are not linear.
Abbreviations: CAUTI, catheter-associated urinary tract infection; CLABSI, central line-associated bloodstream infection; GI, gastrointestinal infection; K, thousand; M, million; SSI, surgical site infection; VAP, ventilator-associated pneumonia; HAP, hospital-acquired pneumonia.